Business Context and Reporting Period
This Form 8-K filing by RXi Pharmaceuticals Corporation (referred to as Phio Pharmaceuticals Corp. in metadata) covers the period ending January 4, 2018. The report details a material corporate action: the implementation of a reverse stock split approved by stockholders in June 2017 and finalized by the Board of Directors on January 3, 2018.
Key Financial Metrics and Capital Structure
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or debt levels. The primary financial data relates to capital structure adjustments:
- Share Count Reduction: Issued and outstanding common stock reduced from approximately 24.3 million to approximately 2.4 million shares.
- Split Ratio: 1-for-10 reverse stock split.
- Warrant Adjustment: Listed warrants converted at a 1-for-10 ratio with an adjusted exercise price of $9.00 per share.
- Fractional Share Payment: Cash payment for fractional shares calculated at $5.46 per share (based on the average closing price of the ten trading days ending January 4, 2018).
Material Changes Versus Prior Period
The material change reported is the reduction in the number of outstanding shares and the corresponding increase in the per-share price and exercise prices of equity instruments. The number of authorized shares was not reduced, thereby increasing the number of shares available for future issuance relative to the outstanding count. No changes were made to the par value ($0.0001) or voting rights of the common stock.
Guidance, Outlook, and Unusual Items
The filing contains no forward-looking guidance, revenue outlook, or management commentary regarding operational performance. The unusual item is the corporate restructuring via the reverse stock split, effective 12:01 a.m. Eastern Time on January 8, 2018. Post-split trading on the NASDAQ Capital Market will continue under symbols "RXII" and "RXIIW" with new CUSIP numbers 74979C 808 and 74979C 121, respectively.
Investor Verification Checklist
- Verify the effective date of the reverse stock split (January 8, 2018) and the timing of post-split trading.
- Confirm the new CUSIP numbers for common stock and warrants to ensure proper account updates.
- Check instructions from brokers or Computershare regarding the exchange of pre-split certificates and the handling of fractional shares.
- Review the adjusted exercise prices for any outstanding stock options or warrants held.
- Confirm that the trading symbols remain "RXII" and "RXIIW" despite the structural changes.